Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Harry J. M. Groen; Wallace L. Akerley; Pierre Jean Souquet; Eckart Laack; Ji-Youn Han; Egbert F. Smit; Aaron Scott Mansfield; Edward B. Garon; Juergen Wolf; Daniel Shao-Weng Tan; Rebecca Suk Heist; Maeve Waldron-Lynch; Sylvie Le Mouhaer; Ngozi Nwana; Monica Giovannini; Sergey Orlov

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Harry J. M. Groen
, Wallace L. Akerley
, Pierre Jean Souquet
, Eckart Laack
, Ji-Youn Han
, Egbert F. Smit
, Aaron Scott Mansfield
, Edward B. Garon
, Juergen Wolf
, Daniel Shao-Weng Tan
, Rebecca Suk Heist
, Maeve Waldron-Lynch
, Sylvie Le Mouhaer
, Ngozi Nwana
, Monica Giovannini
, Sergey Orlov

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	38
Issue number	15
Publication status	Published - 20-May-2020

Handle.net

Persistent link

Cite this

Groen, H. J. M., Akerley, W. L., Souquet, P. J., Laack, E., Han, J.-Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Wolf, J., Tan, D. S.-W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., & Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. Journal of Clinical Oncology, 38(15).

@article{dde86604bc5a4d8280086485965a8136,

title = "Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.",

author = "Groen, \{Harry J. M.\} and Akerley, \{Wallace L.\} and Souquet, \{Pierre Jean\} and Eckart Laack and Ji-Youn Han and Smit, \{Egbert F.\} and Mansfield, \{Aaron Scott\} and Garon, \{Edward B.\} and Juergen Wolf and Tan, \{Daniel Shao-Weng\} and Heist, \{Rebecca Suk\} and Maeve Waldron-Lynch and \{Le Mouhaer\}, Sylvie and Ngozi Nwana and Monica Giovannini and Sergey Orlov",

year = "2020",

month = may,

day = "20",

language = "English",

volume = "38",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "AMER SOC CLINICAL ONCOLOGY",

number = "15",

}

Groen, HJM, Akerley, WL, Souquet, PJ, Laack, E, Han, J-Y, Smit, EF, Mansfield, AS, Garon, EB, Wolf, J, Tan, DS-W, Heist, RS, Waldron-Lynch, M, Le Mouhaer, S, Nwana, N, Giovannini, M & Orlov, S 2020, 'Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.', Journal of Clinical Oncology, vol. 38, no. 15.

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. / Groen, Harry J. M.; Akerley, Wallace L.; Souquet, Pierre Jean et al.
In: Journal of Clinical Oncology, Vol. 38, No. 15, 20.05.2020.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC)

T2 - results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

AU - Groen, Harry J. M.

AU - Akerley, Wallace L.

AU - Souquet, Pierre Jean

AU - Laack, Eckart

AU - Han, Ji-Youn

AU - Smit, Egbert F.

AU - Mansfield, Aaron Scott

AU - Garon, Edward B.

AU - Wolf, Juergen

AU - Tan, Daniel Shao-Weng

AU - Heist, Rebecca Suk

AU - Waldron-Lynch, Maeve

AU - Le Mouhaer, Sylvie

AU - Nwana, Ngozi

AU - Giovannini, Monica

AU - Orlov, Sergey

PY - 2020/5/20

Y1 - 2020/5/20

M3 - Meeting Abstract

SN - 0732-183X

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -